Theranostics Diagram - Cancer Treatment

News

1 years ago

Dr Danielle Meyrick (Chief Scientific Officer) & A/Prof Nat Lenzo (Medical Director) recently published an article titled "PSMA | Prostate Cancer Theranostics" for the Prostate Cancer Research Institute (PCRI). Read Here >>> goo.gl/sLukvS ... See MoreSee Less

PSMA | Prostate Cancer Theranostics

pcri.org

The mainstays of diagnostic investigations for prostate cancer for many decades have been physical examination, blood tests for PSA levels, and biopsy. Imaging investigations, mainly CT, bone scan, specialized MRI techniques, and the recently developed PSMA theranostic imaging, give additional…

View on Facebook

Theranostics Australia

1 years ago

SNMMI Image of the Year: PSMA PET Imaging of Theranostic for Advanced Prostate Cancer >> goo.gl/YjbHyA ... See MoreSee Less

SNMMI Image of the Year: PSMA PET Imaging of Theranostic for Advanced Prostate Cancer - SNMMI

snmmi.org

In the battle against metastatic castrate-resistant prostate cancer, studies have demonstrated a high response rate to radionuclide therapy targeting PSMA with the radionuclide lutetium-177. At the SNMMI 2018 Annual Meeting, researchers reported on a phase II prospective trial. Using gallium-68-PSMA...

View on Facebook

Theranostics Australia

1 years ago

The Clinical Oncology Society of Australia (COSA) has recently published a position statement on Exercise in Cancer Care. COSA has called for “exercise to be embedded as part of standard practice in cancer care and to be viewed as an adjunct therapy that helps counteract the adverse effects of cancer and its treatment.” Read More >> goo.gl/r2R3MK ... See MoreSee Less

Photo

View on Facebook

Theranostics Australia

1 years ago

THE LANCET ONCOLOGY: [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. goo.gl/oNzhvP ... See MoreSee Less

Photo

View on Facebook

Theranostics Australia

1 years ago

PATIENT POV - The Sydney Morning Herald also published an article about Lutetium-177 PSMA therapy, interviewing a 76yo patient who "had exhausted all conventional treatments but one". Read More>>> goo.gl/otq3ST ... See MoreSee Less

From Lucas Heights to PeterMac, new prostate therapy is a game-changer

smh.com.au

Experimental treatment, ignored by big pharma companies, and being trialled at Melbourne’s Peter MacCallum Cancer Centre has had some 'very exciting' results.

View on Facebook

View on Facebook